United Gene High-Tech Group Limited announced the board will inform based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended December 31, 2013, the group is expected to record a substantial increase in the consolidated net loss for the six months ended December 31, 2013 as compared with the corresponding period in 2012, due to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited.
Innovative Pharmaceutical Biotech Limited
Equities
399
BMG4783W1073
Industrial Machinery & Equipment
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.229 HKD | +0.44% |
|
-0.43% | +4.57% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.57% | 50.32M | |
+10.83% | 44.36B | |
+12.08% | 7.38B | |
+20.27% | 7.37B | |
-21.66% | 4.38B | |
+19.61% | 1.44B | |
-2.47% | 1.43B | |
+12.37% | 1.43B | |
+23.71% | 1.13B | |
+1.72% | 1B |
- Stock Market
- Equities
- 399 Stock
- News Innovative Pharmaceutical Biotech Limited
- United Gene High-Tech Group Limited Provides Earnings Guidance for the Six Months Ended December 31, 2013